
Inmode Ltd (INMD) Stock Forecast & Price Target
Inmode Ltd (INMD) Analyst Ratings
Bulls say
InMode Ltd demonstrated robust growth in the second quarter of 2025, achieving sales of 971 systems and increasing its global installed base to approximately 28,855 units, which includes around 12,347 units in the U.S., reflecting a 3.4% rise from the previous quarter. The company reported an impressive operating margin of 27.5%, surpassing expectations and showing a year-over-year improvement of 40 basis points. Additionally, the domestic sales of $49.7 million represent a significant positive turnaround, with a growth rate of 9% compared to a decline of 7% in the prior quarter, indicating an upward trend in consumer and physician interest in aesthetic treatments.
Bears say
InMode Ltd faces a negative outlook primarily due to expected contraction in gross margins, which may hinder overall profitability despite its historically high margins relative to the med tech sector. The company's earnings per share (EPS) growth is projected to lag behind revenue growth, indicating potential challenges in translating sales into profit. Furthermore, the bear case scenario predicts a revenue compound annual growth rate (CAGR) of less than 5% over the next few years, driven by weaker growth from existing products and slower adoption rates for new offerings.
This aggregate rating is based on analysts' research of Inmode Ltd and is not a guaranteed prediction by Public.com or investment advice.
Inmode Ltd (INMD) Analyst Forecast & Price Prediction
Start investing in Inmode Ltd (INMD)
Order type
Buy in
Order amount
Est. shares
0 shares